Identification of viral activators of the HSV-2 UL13 protein kinase
Journal of Virology · 2025
DOI: 10.1128/jvi.01165-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Naoto Koyanagi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Virology, Department of Microbiology and Immunology, the Institute of Medical Science, The University of Tokyo, Minato-ku, Toky…. Hauptthemen laut MEDLINE: Herpesvirus 2, Human, Protein Kinases, Peptide Elongation Factor 1, Viral Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Science Foundation, Grant for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Science, Sports and Technology of Japan, Grant for Transformative Research Areas from the Ministry of Education, Culture, Science, Sports and Technology of Japan.
Abstract (Originalsprache)
Although previous studies reported that the herpes simplex virus 2 (HSV-2) UL13 protein kinase mediates the phosphorylation of elongation factor 1δ (EF-1δ) in infected cells, we found here that individual expression of UL13 was insufficient to induce phosphorylation of EF-1δ in mammalian cells. This led us to hypothesize that HSV-2 UL13 requires viral cofactors for full kinase activity and prompted us to identify such cofactors. Our results were as follows. (i) Co-expression of UL13 with UL55 or Us10 significantly enhanced phosphorylation of EF-1δ compared to UL13 alone. (ii) UL13 was co-precipitated with UL55 or Us10 upon co-expression, and its kinase activity was significantly increased in their presence, as demonstrated by in vitro kinase assays. (iii) In HSV-2-infected cells, UL13 was co-precipitated with Us10 and UL55. (iv) The UL55-null mutation significantly reduced phosphorylation of EF-1δ in HSV-2-infected cells, whereas the Us10-null mutation had little effect; however, the double-null mutation further decreased the phosphorylation compared to the UL55-null mutation alone. (v) The UL55-null mutation, but not the Us10-null mutation, significantly reduced HSV-2 replication and cell-cell spread in U2OS cells to levels comparable to those observed with the UL13 kinase-dead mutation. These results suggest that UL55 acts as a principal activator of UL13 in HSV-2-infected cells, whereas Us10 serves as an auxiliary activator. Moreover, the role of UL13 kinase activity in HSV-2 replication and cell-cell spread in U2OS cells appears to be largely dependent on UL55. IMPORTANCE Herpesviruses encode conserved protein kinases (CHPKs) that often target cellular cyclin-dependent kinase (CDK) phosphorylation sites. CHPKs from beta- and gammaherpesviruses can exhibit these CDK-like functions even when individually expressed in mammalian cells. In contrast, CHPKs from alphaherpesviruses display these CDK-like functions in infected cells, but not upon individual expression, suggesting that they require additional viral factors to exhibit full kinase activity. In this study, we focused on HSV-2 UL13, an alphaherpesvirus CHPK, and identified HSV-2 UL55 and Us10 as viral activators of UL13. In HSV-2-infected cells, UL55 functions as a principal activator of UL13, while Us10 serves as an auxiliary activator. Importantly, the contribution of UL13 kinase activity to HSV-2 replication and cell-cell spread appears to be largely dependent on the presence of UL55. Our findings uncover a previously unrecognized mechanism of CHPK regulation in alphaherpesviruses and provide new insights into the evolutionary diversification of viral kinase control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Virology, Department of Microbiology and Immunology, the Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
- Department of Infectious Disease Control, International Research Center for Infectious Diseases, the Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.
- Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Minato, Tokyo, Japan.
- The University of Tokyo, Pandemic Preparedness, Infection and Advanced Research Center, Minato-ku, Tokyo, Japan.
ORCID-Profile: Naoto Koyanagi, Yasushi Kawaguchi
Förderung
- Takeda Science Foundation
- Grant for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Science, Sports and Technology of Japan
- Grant for Transformative Research Areas from the Ministry of Education, Culture, Science, Sports and Technology of Japan
- Japan Science and Technology Agency
- Mitsubishi Foundation
- Waksman Foundation of Japan
- GlaxoSmithKline Japan
- International Joint Research Project of the Institute of Medical Science, the University of Tokyo
Zitieren
APA
Koyanagi, N., Takeshima, K., Shio, S., Maruzuru, Y., Kato, A., & Kawaguchi, Y. (2025). Identification of viral activators of the HSV-2 UL13 protein kinase. Journal of Virology. https://doi.org/10.1128/jvi.01165-25
Vancouver
Koyanagi N, Takeshima K, Shio S, Maruzuru Y, Kato A, Kawaguchi Y. Identification of viral activators of the HSV-2 UL13 protein kinase. Journal of Virology. 2025. doi:10.1128/jvi.01165-25
BibTeX
@article{Koyanagi2025,
author = {Koyanagi, Naoto and Takeshima, Kosuke and Shio, Saori and Maruzuru, Yuhei and Kato, Akihisa and Kawaguchi, Yasushi},
title = {Identification of viral activators of the HSV-2 UL13 protein kinase},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.01165-25}
}
EUVIMED